Prelude Therapeutics

Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

- Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors  PRT543 and PRT811 to be Presented in 4Q21 –

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

Prelude Therapeutics Inc's (NASDAQ:PRLD) share price represents “a particularly attractive buying opportunity,” and the stock has catalysts in the back half of the year, according to BofA Securities. The Prelude Therapeutics Analyst: Tazeen Ahmad upgraded Prelude Therapeutics from Neutral to Buy and maintained a $60 price target.

Why BofA Is Turning Bullish On Prelude Therapeutics

- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 -

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update

Prelude Therapeutics (PRLD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Prelude Therapeutics (PRLD) Enters Oversold Territory

WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences:

Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences

WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share, which includes the exercise in full of the underwriters' option to purchase an additional 375,000 shares of its voting common stock. The aggregate gross proceeds from this offering were $172.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Prelude.

Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its upsized public offering of 2,208,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share. The aggregate gross proceeds from this offering are expected to be $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Prelude. In addition, Prelude has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of voting common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 11, 2021, subject to the satisfaction of customary closing conditions.

Prelude Therapeutics Announces Pricing of Upsized Public Offering

- Completed I nitial P ublic O ffering of C ommon S tock, R aising G ross P roceeds of ~$ 181.9M -

Prelude Therapeutics Announces Third Quarter 2020 Financial Results

WILMINGTON, Del., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the first patient has been dosed in its first-in-human Phase 1 open-label, multicenter, dose-escalation study of PRT1419 in patients with relapsed/refractory hematologic malignancies. PRT1419, the Company’s third clinical candidate, is designed to be an orally available, potent and selective MCL1 inhibitor.

Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies

WILMINGTON, Del., Sept.  29, 2020  (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public offering of 9,573,750 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1,248,750 additional shares of common stock, at a public offering price of $19.00 per share. The aggregate gross proceeds to Prelude Therapeutics from the offering were approximately $181.9 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Prelude Therapeutics.

Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Amesite Operating

Bentley Systems

Corsair Gaming

GoodRx Holdings

Greenwich Lifesciences

Graybug Vision

Laird Superfood

PMV Pharmaceuticals

Array Technologies

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

WILMINGTON, Del., Sept.  24, 2020  (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19.00 per share. The gross proceeds to Prelude, before deducting underwriting commissions and offering expenses, are expected to be approximately $158.2 million. All of the shares of common stock are being offered by Prelude Therapeutics. In addition, Prelude Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,248,750 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Prelude Therapeutics Announces Pricing of Initial Public Offering

Prelude Therapeutics has filed to raise $150 million in a U.S. IPO.

Prelude Therapeutics Finalizes IPO Terms

News for Prelude Therapeutics Stock (PRLD)